Cytokinetics launches ASPEN-HCM and analysts rate Cytokinetics stock a Buy

Published on 10/01/2026 at 17:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 28.62 million, 62.70 percent above consensus. For Cytokinetics stock, reported Q2 2026 net loss was USD 198.8 million.

Cytokinetics stock, biotechnology, ASPEN-HCM, MYQORZO, analyst ratings, Nasdaq, Illustration mit AI erstellt.

Cytokinetics (ISIN US2328281044) launched ASPEN-HCM on September 30, 2026, a real-world study of MYQORZO in symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics said the study will track safety, effectiveness and healthcare resource use. MarketBeat reported on September 19, 2026, that 18 of 20 covering brokerages rated the stock Buy, with one Hold and one Sell.

ASPEN-HCM targets real-world evidence

The prospective, multicenter study is led by the University of California, San Francisco and spans 13 cardiology practices and hypertrophic cardiomyopathy centers of excellence.

Cytokinetics aims to enroll 400 patients over 12 to 36 months. The study will track left ventricular ejection fraction, treatment discontinuations, outflow tract gradients, New York Heart Association classification and patient-reported outcomes.

The launch also carries a clear safety dimension. The company states that MYQORZO can reduce left ventricular ejection fraction and cause heart failure, so treatment requires echocardiogram monitoring and operates through a restricted risk-management program.

Revenue beat meets heavy investment

In the second quarter of 2026, revenue reached USD 28.62 million, versus a USD 17.59 million consensus estimate. That is 62.70 percent above consensus, while reported revenue fell 57.10 percent year over year, according to MarketBeat.

The same quarter produced a reported net loss of USD 198.8 million, or USD 1.50 per diluted share, compared with a consensus loss of USD 1.63 per share. Cash and cash equivalents stood at USD 255.3 million at June 30, 2026, while operating cash flow was negative USD 159.8 million.

That contrast defines the investment case: MYQORZO is creating commercial revenue, but the company is still funding a costly cardiovascular pipeline. The real-world study may add evidence for prescribing decisions, while the financial figures show why execution and cash use remain central.

Analysts see a higher target

MarketBeat listed a consensus target of USD 103.37 and said several firms had raised targets to between USD 110 and USD 118. The article also cited Needham lifting its target from USD 102.00 to USD 112.00 and Barclays raising its target from USD 95.00 to USD 110.00 on August 13, 2026.

Market data on October 1, 2026, put Cytokinetics' market capitalization at USD 8.2 billion. The 52-week range was USD 54.30 to USD 88.31, leaving the stock's valuation tied to both MYQORZO uptake and the pipeline's regulatory progress.

Stock facts and trading context

Cytokinetics is listed on Nasdaq under the ticker CYTK and operates in the Healthcare sector's Biotechnology industry. Its lead commercial product is MYQORZO, while aficamten remains central to expansion into additional hypertrophic cardiomyopathy indications.